Amgen vs Gilead Sciences
Amgen is the larger business, with $36.75bn of revenue in fiscal 2025 against $29.44bn for Gilead Sciences (1.2 times as much). Amgen grew faster (10.0% against 2.4%). Gilead Sciences kept more of each dollar of sales as profit: a net margin of 28.9% against 21.0%. Gilead Sciences carries less debt relative to equity (109.8% against 630.7%).
| Latest fiscal year | AmgenAMGN, 2025 | Gilead SciencesGILD, 2025 |
|---|---|---|
| Revenue | $36.75bn | $29.44bn |
| Revenue growth | 10.0% | 2.4% |
| Net income | $7.71bn | $8.51bn |
| Operating margin | 24.7% | 34.0% |
| Net margin | 21.0% | 28.9% |
| Return on equity | 106.1% | 40.5% |
| Free cash flow | $8.10bn | $9.46bn |
| Cash | $9.13bn | $7.56bn |
| Total debt | $54.60bn | $24.94bn |
| Debt to equity | 630.7% | 109.8% |
| Dividend per share | $9.66 | $3.16 |
| Dividend yield | 2.1% | 1.9% |
| Share buybacks | $0 | $1.92bn |
| Employees | — | 17,000 |
| Market value | $249.43bn | $208.99bn |
| Price vs our value range | Within our value range | Within our value range |
| Moat score | 89 (Strong) | 79 (Strong) |
| Insider trades, 12 months | 0 buys, 14 sales | 0 buys, 83 sales |